Early treatment with Novartis' Mayzent stalls secondary progressive MS: study

Novartis is looking to grow its new multiple sclerosis drug Mayzent in a crowded field, and with Gilenya generics threatening, the newer MS medicine may need to carry even more weight. It just racked up some new data that could help.